The impact of prediabetes on cerebrovascular risk among patients with gastrointestinal malignancies.

K Kanishka Uttam Chandani (4Mayo Clinic, Hematology-Oncology, Phoenix, United States) S Siddharth Pravin Agrawal (New York Medical College, Landmark Medical Center, Woonsocket, RI) M Maharshi Raval (St. Elizabeth's Medical Center, Boston, MA) M Mohamed Ayaan Sait (Smt. NHL Municipal Medical College, Ahmedabad, India) A Apoorva Kondapally (6Asante Rogue Regional Medical Center, Medford, United States) A Ahmed Nadeem (1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States) T Tanuj Sharma (New York Medical College/Landmark Medical Center, Woonsocket, RI) A Ambreen Ijaz (1Kent Hospital, Warwick, United States) S Sajid Siddiq (New York Medical College/Landmark Medical Center, Woonsocket, RI) A Ashish V. Chintakuntlawar (Department of Oncology, Mayo Clinic Arizona, Phoenix, AZ) K Kriti Mittal (UMass Chan Medical School, Worcester, MA)

Abstract

817 Background: Cancer screening ingastrointestinal (GI) malignancies has translated into an improvement in overall survival due to detection at an earlier stage. The majority of survivors (up to 67%) are over the age of 65. The impact of metabolic profiles on cerebrovascular events amongst this population of cancer survivors is unclear. Methods: Data from the NIS database from 2016 to 2020 were reviewed for patients with seven GI malignancies. Analysis was performed based on the presence or absence of prediabetes using ICD-10 codes. Baseline characteristics, comorbidities, and cerebrovascular outcomes were studied in these 2 cohorts. Results: 1,532,250 hospitalizations of patients with seven GI malignancies, namely colorectal cancer (CRC), pancreatic cancer, hepatocellular carcinoma (HCC), gastric cancer, small intestinal cancer, cholangiocarcinoma, and esophageal cancer, were evaluated and divided into two subgroups: prediabetics (15,610) and non-prediabetics (1,516,640). Prediabetics with GI malignancies as compared to non-prediabetics with GI malignancies were noted to be older (67.7 years vs. 65.64 years), with higher total hospitalization charges (USD 87,267 vs. USD 80,173), greater rates of elective admissions (34.92% vs. 25.89%) but a lower length of stay (6.018 days vs. 6.53 days). Prediabetic patients with GI malignancies were noted to have a higher prevalence of obesity (18.64% vs. 7.69%), dyslipidemia (52.99% vs. 26.16%), and hypertension (49.59% vs. 39.37%). Prediabetics with CRC, as compared to non-prediabetics, had higher adjusted odds ratios (aORs) of occlusion/stenosis of precerebral or cerebral arteries not leading to cerebral infarction, and cerebral infarction, with aORs of 2.03 (95% CI 1.24-3.30, p 0.004), and 1.63 (95% CI 1.01-2.63, p 0.045) respectively. Additionally, prediabetics with pancreatic cancer had a higher aOR of cerebral infarction as compared to non-prediabetics, with aOR of 2.42 (95% CI 1.70-3.44, p<0.001). Conclusions: Prediabetic patients with CRC had higher aORs of cerebral infarction and occlusion/stenosis of precerebral arteries not leading up to cerebral infarction, and prediabetics with pancreatic cancer had twice the risk of cerebral infarction as compared to non-prediabetics. This study highlights the impact of prediabetes, a modifiable risk factor, on cerebrovascular outcomes in patients with GI malignancies.

Article Details

Volume / Issue Vol. 43, Issue 4_suppl
Published February 01, 2025
Pages 817-817
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (11)

K

Kanishka Uttam Chandani

4Mayo Clinic, Hematology-Oncology, Phoenix, United States

S

Siddharth Pravin Agrawal

New York Medical College, Landmark Medical Center, Woonsocket, RI

M

Maharshi Raval

St. Elizabeth's Medical Center, Boston, MA

M

Mohamed Ayaan Sait

Smt. NHL Municipal Medical College, Ahmedabad, India

A

Apoorva Kondapally

6Asante Rogue Regional Medical Center, Medford, United States

A

Ahmed Nadeem

1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States

T

Tanuj Sharma

New York Medical College/Landmark Medical Center, Woonsocket, RI

A

Ambreen Ijaz

1Kent Hospital, Warwick, United States

S

Sajid Siddiq

New York Medical College/Landmark Medical Center, Woonsocket, RI

A

Ashish V. Chintakuntlawar

Department of Oncology, Mayo Clinic Arizona, Phoenix, AZ

K

Kriti Mittal

UMass Chan Medical School, Worcester, MA